Signal2026-04-15
ClinicalTrials.gov

[PHASE4] Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)

Part of

Emerging Biomolecular Targets In Therapy

Open primary sourceSee the whole picture